Exchange & Returns Information
Review Details
(0)
| Generic For | SPRYCEL |
|---|---|
| Active Ingredient | DASATINIB |
| Strength | 50MG |
| Manufacturer | CIPLA |
| Pack Size | Price Per Unit | Unit Price | QTY | CART | Best Coupon Price MAX DISCOUNT |
|---|---|---|---|---|---|
| 1 BOX - 60 TABLETS | $ 1.17 | $ 70.00 |
$ 59.50
Apply ZARVY26 (-15%)
You save $ 10.50
|
||
| 2 BOXES - 120 TABLETS | $ 1.23 | $ 148.00 |
$ 125.80
Apply ZARVY26 (-15%)
You save $ 22.20
|
||
| ★ Best Value 3 BOXES - 180 TABLETS | $ 1.26 | $ 226.00 |
$ 192.10
Apply ZARVY26 (-15%)
You save $ 33.90
|
Reference information will be available soon.
Dasatrue 50 is a generic formulation of dasatinib indicated for the treatment of Philadelphia chromosome–positive (Ph+) leukemias. As a potent second-generation tyrosine kinase inhibitor (TKI), it inhibits both BCR-ABL and SRC-family kinases, enabling rapid cytogenetic and molecular responses even in imatinib-resistant cases.
Its capacity for central nervous system (CNS) penetration makes it particularly effective in preventing or managing leukemic CNS involvement. Dasatrue 50 is used across both adult and pediatric populations, providing tailored dosing options according to disease stage and patient weight.
AntiCancer Drugs > Chronic Myeloid Leukemia (CML)
Dasatrue 50 is indicated for patients with Ph+ CML, including those newly diagnosed in the chronic phase and those with disease progression or intolerance to prior therapies such as imatinib. Its broader kinase inhibition accelerates remission induction and improves outcomes in high-risk and advanced CML cases.
> Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Dasatrue 50 is also approved for Ph+ ALL, particularly in relapsed or refractory cases. It may be used as monotherapy or in combination with chemotherapy, and is frequently incorporated into pre-transplant conditioning regimens. Its ability to penetrate the blood–brain barrier aids in CNS prophylaxis and treatment.
> Myeloid and Lymphoid Blast Crisis
In CML patients who progress to blast crisis, Dasatrue 50 serves as a salvage option with documented rapid cytogenetic response, making it suitable for urgent intervention prior to stem cell transplantation (HSCT).
Inhibits BCR-ABL tyrosine kinase and SRC-family kinases
Effective against imatinib-resistant BCR-ABL mutations
CNS penetration provides efficacy in cases with CNS involvement in leukemias
Induces rapid hematologic and cytogenetic responses in Ph+ leukemias
Suitable for both frontline and salvage settings
1. Adult Dose – Leukemia
Chronic Phase CML: 100 mg orally once daily
Accelerated Phase CML / Blast Phase CML / Ph+ ALL: 140 mg orally once daily
Duration: Continue therapy until disease progression or the occurrence of unacceptable toxicity. Patients should be closely monitored for pleural effusion, cytopenias, and cardiac abnormalities. Dose adjustments should be made accordingly. Regular CBCs and ECGs are essential during treatment.
2. Pediatric Dose – Leukemia
10–<20 kg: 40 mg orally once daily
20–<30 kg: 60 mg orally once daily
30–<45 kg: 70 mg orally once daily
≥45 kg: 100 mg orally once daily
Notes: Pediatric dosing should be reassessed every 3 months or upon significant weight change. For Ph+ ALL, treatment should begin by day 15 of induction chemotherapy and continue for up to 2 years. Tablets are not recommended for children weighing under 10 kg.
Store in a dry environment at 15–30°C (59–86°F). Keep in the original container away from direct sunlight and moisture. Do not crush or split the tablets. If tablets are broken, handle with gloves. Keep out of reach of children.
- Common: fatigue, headache, nausea, abdominal discomfort - Hematologic: anemia, thrombocytopenia, neutropenia - Respiratory: pleural effusion, dyspnea - Cardiovascular: QT prolongation, palpitations - Gastrointestinal: diarrhea, vomiting - Others: fluid retention, skin rash, elevated liver enzymes
No reviews yet. Be the first to review this product!
No combo deals available at the moment.
